Restricted accessResearch articleFirst published online 2016-01-22
Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ 4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer’s Disease
A common polymorphism of the butyrylcholinesterase gene, the K-variant (BCHE-K) is associated with reduced butyrylcholinesterase (BuChE) activity. Insufficient studies exist regarding the frequency and role of BCHE-K in dementias.
Objective:
To determine the association of BCHE-K and APOEɛ4 with diagnosis and rate of cognitive decline in dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD) patients.
Methods:
Genomic DNA from 368 subjects (108 AD, 174 DLB, and 86 controls) from two routine clinical cohort studies in Norway; DemVest and TrønderBrain, were genotyped for BCHE-K and APOEɛ4. The mild dementia DemVest subjects received annual Mini-Mental State Examination assessments for five years.
Results:
BCHE-K frequency was lower in DLB (33.9% ; p < 0.01) than in control subjects (51.2%), and was numerically lower in AD as well (38.9% ; p = 0.11). More rapid cognitive decline was associated with the APOEɛ4 genotype, but not with the BCHE-K genotype. In an exploratory analysis of patients who completed all five follow-up visits, there was greater cognitive decline in BCHE-K carriers in the presence of the APOEɛ4 allele than in the absence of these polymorphisms.
Conclusion:
BCHE-K is associated with a reduced risk for AD and DLB whereas APOEɛ4 is associated with more rapid cognitive decline. The greater cognitive decline in individuals with both APOEɛ4 and BCHE-K alleles require prospective confirmation in well-controlled trials.
BohnenNI, AlbinRL (2011) The cholinergic system and Parkinson disease. Behav Brain Res221, 564–573.
2.
SilverA (1974) The biology of cholinesterase. In Frontiers of Biology, Vol. 36, NeuergerA, TatumEL, eds. Elsevier, North-Holland, Amsterdam, pp. 58–67.
3.
Darreh-ShoriT, VijayaraghavanS, AeinehbandS, PiehlF, LindblomRP, NilssonB, EkdahlKN, LangstromB, AlmkvistO, NordbergA (2013) Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer’sdisease. Neurobiol Aging34, 2465–2481.
LaneRM, Darreh-ShoriT (2015) Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value. J Alzheimers Dis44, 1039–1062.
6.
AllderdicePW, GardnerHA, GalutiraD, LockridgeO, LaDuBN, McAlpinePJ (1991) The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26. Genomics11, 452–454.
7.
ProdyCA, Zevin-SonkinD, GnattA, GoldbergO, SoreqH (1987) Isolation and characterization of full-length cDNA clones coding for cholinesterase from fetal human tissues. Proc Natl Acad Sci U S A84, 3555–3559.
8.
La DuBN, BartelsCF, NogueiraCP, ArpagausM, LockridgeO (1991) Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing. Cell Mol Neurobiol11, 79–89.
9.
LaDu BN, BartelsCF, NogueiraCP, HajraA, LightstoneH, Van der SpekA, LockridgeO (1990) Phenotypic and molecular biological analysis of human butyrylcholinesterase variants. Clin Biochem23, 423–431.
10.
RoychoudhuryAK, NeiM (1988) Human polymorphic genes: World distribution, Oxford University Press, USA.
11.
BartelsCF, JensenFS, LockridgeO, van der SpekAF, RubinsteinHM, LubranoT, La DuBN (1992) DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet50, 1086–1103.
12.
Darreh-ShoriT, SiaweshM, MousaviM, AndreasenN, NordbergA (2012) Apolipoprotein epsilon4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer’s disease. J Alzheimers Dis28, 443–458.
13.
BallardC, MorrisC, KalariaR, McKeithI, PerryR, PerryE (2005) The k variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients. Dement Geriatr Cogn Disord19, 357–360.
14.
LehmannDJ, NagyZ, LitchfieldS, BorjaMC, SmithAD (2000) Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer’s disease. Hum Genet106, 447–452.
15.
RamananVK, RisacherSL, NhoK, KimS, SwaminathanS, ShenL, ForoudTM, HakonarsonH, HuentelmanMJ, AisenPS, PetersenRC, GreenRC, JackCR, KoeppeRA, JagustWJ, WeinerMW, SaykinAJ (2014) APOE and BCHE as modulators of cerebral amyloid deposition: A florbetapir PET genome-wide association study. Mol Psychiatry19, 351–357.
16.
GiacobiniE (2003) Butyrylcholinesterase: Its function and inhibitors, Taylor & Francis.
17.
LehmannD, SmithAD. (2003) Butyrylcholinesterase K variant in Alzheimer’s disease. In Butyrylcholinesterase: Its function and inhibitors, GiaobiniE, ed. Martin Dunitz, London, pp. 135–148.
18.
Alvarez-ArcayaA, CombarrosO, LlorcaJ, Sanchez-GuerraM, BercianoJ, Fernandez-ViaderoC, PenaN (2000) The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer’s disease in women. Acta Neurol Scand102, 350–353.
19.
HiltunenM, MannermaaA, HelisalmiS, KoivistoA, LehtovirtaM, RyynanenM, RiekkinenPSr, SoininenH (1998) Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer’s disease patients. Neurosci Lett250, 69–71.
20.
MattilaKM, RinneJO, RoyttaM, LaippalaP, PietilaT, KalimoH, KoivulaT, FreyH, LehtimakiT (2000) Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer’s disease and in Parkinson’s disease with coexisting Alzheimer pathology. J Med Genet37, 766–770.
21.
LaneR, FeldmanHH, MeyerJ, HeY, FerrisSH, NordbergA, Darreh-ShoriT, SoininenH, PirttilaT, FarlowMR, SfikasN, BallardC, GreigNH (2008) Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer’s disease. Pharmacogenet Genomics18, 289–298.
22.
RayganiAV, ZahraiM, SoltanzadehA, DoostiM, JavadiE, PourmotabbedT (2004) Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer’s disease. Neurosci Lett371, 142–146.
23.
TilleyL, MorganK, GraingerJ, MarstersP, MorganL, LoweJ, XuerebJ, WischikC, HarringtonC, KalshekerN (1999) Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer’s disease. Eur J Hum Genet7, 659–663.
24.
WiebuschH, PoirierJ, SevignyP, SchappertK (1999) Further evidence for a synergistic association between i epsilon4 and BCHE-K in confirmed Alzheimer’s disease. Hum Genet104, 158–163.
LawsS, TaddeiK, FisherC, SmallD, ClarnetteR, HallmayerJ, BrooksW, KwokJ, SchofieldP, GandyS (1999) Evidence that the butyrylcholinesterase K variant can protect against late-onset Alzheimer’s Disease. Alzheimers Rep2, 219–223.
27.
SingletonAB, GibsonAM, EdwardsonJA, McKeithIG, MorrisCM (1998) Butyrylcholinesterase K: An association with dementia with Lewy bodies. Lancet351, 1818.
28.
LaneR, HeY, MorrisC, LeverenzJB, EmreM, BallardC (2009) BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord24, 392–400.
29.
BiglerED, LowryCM, AndersonCV, JohnsonSC, TerryJ, SteedM (2000) Dementia, quantitative neuroimaging, and apolipoprotein E genotype. AJNR Am J Neuroradiol21, 1857–1868.
30.
JonkerC, SchmandB, LindeboomJ, HavekesLM, LaunerLJ (1998) Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol55, 1065–1069.
31.
LaneRM, FarlowMR (2005) Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer’s disease. J Lipid Res46, 949–968.
32.
HolmesC, BallardC, LehmannD, David SmithA, BeaumontH, DayIN, Nadeem KhanM, LovestoneS, McCulleyM, MorrisCM, MunozDG, O’BrienK, RussC, Del SerT, WardenD (2005) Rate of progression of cognitive decline in Alzheimer’s disease: Effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry76, 640–643.
33.
O’BrienKK, SaxbyBK, BallardCG, GraceJ, HarringtonF, FordGA, O’BrienJT, SwanAG, FairbairnAF, WesnesK, del SerT, EdwardsonJA, MorrisCM, McKeithIG (2003) Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics13, 231–239.
34.
LaneRM, HeY (2009) Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon 4, and hyperhomocysteinemia in neurodegenerative dementias. Med Hypotheses73, 230–250.
35.
AarslandD, RongveA, NoreSP, SkogsethR, SkulstadS, EhrtU, HoprekstadD, BallardC (2008) Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord26, 445–452.
36.
BergeG, SandoSB, RongveA, AarslandD, WhiteLR (2014) Apolipoprotein E epsilon2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. J Neurol Neurosurg Psychiatry85, 1227–1231.
37.
SandoSB, MelquistS, CannonA, HuttonML, SletvoldO, SaltvedtI, WhiteLR, LydersenS, AaslyJO (2008) APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer’s disease: A case control study from centralNorway. BMC Neurol8, 9.
38.
JonssonT, StefanssonH, SteinbergS, JonsdottirI, JonssonPV, SnaedalJ, BjornssonS, HuttenlocherJ, LeveyAI, LahJJ, RujescuD, HampelH, GieglingI, AndreassenOA, EngedalK, UlsteinI, DjurovicS, Ibrahim-VerbaasC, HofmanA, IkramMA, van DuijnCM, ThorsteinsdottirU, KongA, StefanssonK (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med368, 107–116.
CaselliRJ, DueckAC, OsborneD, SabbaghMN, ConnorDJ, AhernGL, BaxterLC, RapcsakSZ, ShiJ, WoodruffBK, LockeDE, SnyderCH, AlexanderGE, RademakersR, ReimanEM (2009) Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med361, 255–263.
43.
MorminoEC, BetenskyRA, HeddenT, SchultzAP, WardA, HuijbersW, RentzDM, JohnsonKA, SperlingRA (2014) Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology82, 1760–1767.
44.
LehmannDJ, JohnstonC, SmithAD (1997) Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer’s disease. Hum Mol Genet6, 1933–1936.
45.
TaskerA, BallardCG, JoachimC, WardenDR, OkelloEJ, PerryRH, KhanN, SmithAD, LehmannDJ, PerryEK (2008) Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients. Neurosci Lett442, 297–299.
